Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2

20260 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov identifier, NCT01722331 (reSURFACE 1), NCT01729754 (reSURFACE 2).

Good health and well-being

Published in: Dermatology and Therapy

Field-Weighted Citation Impact: 0.00